Show news: from last 30 days (default), 60 days, 90 days, last visit or all

IV carbamazepine authorized in the US

12th October 2016

The FDA has authorized a parenteral formulation of carbamazepine (Carnexiv; Lundbeck) for short-term replacement therapy for oral forms of the drug in adults with certain seizure types when oral administration is temporarily not feasible.

The IV total daily dose is 70% of the PO total daily dose of carbamazepine, and should be divided equally into four infusions to be administered q6h. Each dose should be diluted in 100mL of diluent and infused IV over 30 minutes.

The company has not yet filed for a marketing authorization in Europe.

click here to view